Elan and Biogen say Tysabri approved in Canada
Last Updated: 2006-10-04 9:00:26 -0400 (Reuters Health) | | | LONDON (Reuters) - Ireland's Elan Corp and U.S. partner Biogen Idec said on Wednesday that Canadian regulators had approved their Tysabri drug as a treatment for relapsing-remitting multiple sclerosis. The drug, which was temporarily suspended after it was linked to a rare but potentially fatal brain disease, was cleared to return in the United States earlier this year, albeit with restrictions on how it is prescribed. | MS News is brought to you by the Consortium of MS Centers as part of the eMS-Health Project funded by an unrestricted grant from Teva Neuroscience.
Copyright © 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world. |
|
CMSC Online 
